This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2009 Jan;23(1):65-6.

Perioperative tyrosine kinase inhibitors for GIST: standard ... or an idea that needs further investigation?

Margaret von Mehren¹, James C Watson

Affiliations

PMID: 19283923
PMCID: PMC2861343

Comment

Perioperative tyrosine kinase inhibitors for GIST: standard ... or an idea that needs further investigation?

Margaret von Mehren et al. Oncology (Williston Park). 2009 Jan.

. 2009 Jan;23(1):65-6.

Authors

Margaret von Mehren¹, James C Watson

Affiliation

¹ Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.

PMID: 19283923
PMCID: PMC2861343

No abstract available

PubMed Disclaimer

Comment on

Perioperative treatment of gastrointestinal stromal tumors.
Fernandes Gdos S, Blanke CD, Freitas D, Guedes R, Hoff PM. Fernandes Gdos S, et al. Oncology (Williston Park). 2009 Jan;23(1):54-61. Oncology (Williston Park). 2009. PMID: 19283922 Review.

Similar articles

Recent advances in therapy for gastrointestinal stromal tumors.
Maki RG. Maki RG. Curr Oncol Rep. 2007 May;9(3):165-9. doi: 10.1007/s11912-007-0017-0. Curr Oncol Rep. 2007. PMID: 17430686 Review.
Perioperative treatment of gastrointestinal stromal tumors.
Fernandes Gdos S, Blanke CD, Freitas D, Guedes R, Hoff PM. Fernandes Gdos S, et al. Oncology (Williston Park). 2009 Jan;23(1):54-61. Oncology (Williston Park). 2009. PMID: 19283922 Review.
Current management of GISTs.
Blanke C. Blanke C. Clin Adv Hematol Oncol. 2010 May;8(5):334. Clin Adv Hematol Oncol. 2010. PMID: 20551892 No abstract available.
Sunitinib for imatinib-resistant GIST.
Joensuu H. Joensuu H. Lancet. 2006 Oct 14;368(9544):1303-4. doi: 10.1016/S0140-6736(06)69489-0. Lancet. 2006. PMID: 17046443 No abstract available.
Controversies in the surgical management of GIST in the era of imatinib.
Raut CP, Bertagnolli MM. Raut CP, et al. Oncology (Williston Park). 2009 Jan;23(1):69, 74-6. Oncology (Williston Park). 2009. PMID: 19283924

See all similar articles

Cited by

(18)FDG-PET at 1-Month Intervals Is a Better Predictive Marker for GISTs That Are Difficult to Be Diagnosed Histopathologically: A Case Report.
Otsuka K, Takahashi M, Nanjo H, Miyazawa H, Iida M, Abe Y, Jin M, Onishi H, Hashimoto M, Yamamoto Y, Shibata H. Otsuka K, et al. Case Rep Oncol Med. 2011;2011:638794. doi: 10.1155/2011/638794. Epub 2011 Oct 11. Case Rep Oncol Med. 2011. PMID: 22606444 Free PMC article.
Prolonged Therapy with Imatinib Mesylate before Surgery for Advanced Gastrointestinal Stromal Tumor Results of a Phase II Trial.
Doyon C, Sidéris L, Leblanc G, Leclerc YE, Boudreau D, Dubé P. Doyon C, et al. Int J Surg Oncol. 2012;2012:761576. doi: 10.1155/2012/761576. Epub 2012 Dec 17. Int J Surg Oncol. 2012. PMID: 23316352 Free PMC article.
Get the GIST? An overview of gastrointestinal stromal tumours.
Watson GA, Kelly D, Melland-Smith M, Gleeson J, McEntee G, Kelly CM, McCaffrey JA. Watson GA, et al. Ir J Med Sci. 2016 May;185(2):319-26. doi: 10.1007/s11845-016-1410-1. Epub 2016 Feb 1. Ir J Med Sci. 2016. PMID: 26833487 Review.

References

1. DeMatteo R, Owzar K, Maki R, et al. Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup phase III trial ACOSOG Z9001 (abstract 10079) J Clin Oncol. 2007;25 suppl 18
1. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial. Lancet. 2004;364:1127–1134. - PubMed
1. Blanke CD, Rankin C, von Mehren M, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the KIT receptor tyrosine kinase: S0033. J ClinOncol. 2008;26:620–625. - PubMed
1. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in advanced gastrointestinal stromal tumors after failure of imatinib: A randomized controlled trial. Lancet. 2006;368:1329–1338. - PubMed
1. Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer. 2006;42:1093–1103. - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
- Europe PubMed Central
- PubMed Central